Latest News on CVRX

Financial News Based On Company


Advertisement
Advertisement

CVRx ( CVRX ) Q2 Revenue Jumps 15%

https://www.fool.com/data-news/2025/08/05/cvrx-cvrx-q2-revenue-jumps-15/
CVRx ( NASDAQ:CVRX ) , a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue ( GAAP ) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million ( GAAP ...

CVRx ( CVRX ) Reports Q2 Loss, Beats Revenue Estimates

https://www.zacks.com/stock/news/2664119/cvrx-cvrx-reports-q2-loss-beats-revenue-estimates
CVRx (CVRX) delivered earnings and revenue surprises of -9.62% and +0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Steris ( STE ) Earnings Expected to Grow: Should You Buy?

https://www.zacks.com/stock/news/2638930/steris-ste-earnings-expected-to-grow-should-you-buy
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference

https://www.globenewswire.com/news-release/2025/07/29/3123213/0/en/CVRx-to-Present-at-the-Canaccord-Genuity-45th-Annual-Growth-Conference.html
MINNEAPOLIS, July 29, 2025 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( "CVRx" ) , a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the ...

CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference - CVRx ( NASDAQ:CVRX )

https://www.benzinga.com/pressreleases/25/07/g46685169/cvrx-to-present-at-the-canaccord-genuity-45th-annual-growth-conference
MINNEAPOLIS, July 29, 2025 ( GLOBE NEWSWIRE ) -- CVRx, Inc.
Advertisement

CVRx ( CVRX ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

https://www.zacks.com/stock/news/2628946/cvrx-cvrx-may-report-negative-earnings-know-the-trend-ahead-of-next-weeks-release
CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025

https://www.globenewswire.com/news-release/2025/07/21/3119049/0/en/CVRx-to-Report-Second-Quarter-2025-Financial-and-Operating-Results-and-Host-Conference-Call-on-August-4-2025.html
MINNEAPOLIS, July 21, 2025 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( "CVRx" ) , a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it ...

CVRx ( CVRX ) Surges 19.0%: Is This an Indication of Further Gains?

https://www.zacks.com/stock/news/2587726/cvrx-cvrx-surges-190-is-this-an-indication-of-further-gains
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CVRx Announces Positive News on Outpatient Payment for Barostim

https://www.benzinga.com/pressreleases/25/07/g46438671/cvrx-announces-positive-news-on-outpatient-payment-for-barostim
MINNEAPOLIS, July 16, 2025 ( GLOBE NEWSWIRE ) -- CVRx, Inc.

CVRx Announces Positive News on Outpatient Payment for Barostim

https://www.globenewswire.com/news-release/2025/07/16/3116282/0/en/CVRx-Announces-Positive-News-on-Outpatient-Payment-for-Barostim.html
MINNEAPOLIS, July 16, 2025 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( "CVRx" ) , a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services ( CMS ) has proposed to keep the Barostim implant procedure as part of the New Technology ...
Advertisement

This International Paper Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - CVRx ( NASDAQ:CVRX ) , International Paper ( NYSE:IP )

https://www.benzinga.com/25/05/45315559/this-international-paper-analyst-turns-bearish-here-are-top-5-downgrades-for-friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Dave To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday - CVRx ( NASDAQ:CVRX ) , CarGurus ( NASDAQ:CARG )

https://www.benzinga.com/25/05/45315016/dave-to-rally-around-17-here-are-10-top-analyst-forecasts-for-friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham cut MKS Instruments, Inc. MKSI price target from $145 to $140.

CVRx ( CVRX ) Reports Q1 Loss, Tops Revenue Estimates

https://www.zacks.com/stock/news/2465681/cvrx-cvrx-reports-q1-loss-tops-revenue-estimates
CVRx (CVRX) delivered earnings and revenue surprises of 5.36% and 0.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

908 Devices Inc. ( MASS ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

https://www.zacks.com/stock/news/2463114/908-devices-inc-mass-may-report-negative-earnings-know-the-trend-ahead-of-next-weeks-release
908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVRx ( CVRX ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

https://www.zacks.com/stock/news/2460252/cvrx-cvrx-may-report-negative-earnings-know-the-trend-ahead-of-next-weeks-release
CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Advertisement

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

https://www.globenewswire.com/news-release/2025/04/24/3067955/0/en/CVRx-to-Report-First-Quarter-2025-Financial-and-Operating-Results-and-Host-Conference-Call-on-May-8-2025.html
MINNEAPOLIS, April 24, 2025 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( "CVRx" ) , a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025.

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025 - CVRx ( NASDAQ:CVRX )

https://www.benzinga.com/pressreleases/25/04/g44996181/cvrx-to-report-first-quarter-2025-financial-and-operating-results-and-host-conference-call-on-may-
MINNEAPOLIS, April 24, 2025 ( GLOBE NEWSWIRE ) -- CVRx, Inc. CVRX ( "CVRx" ) , a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025.

Crude Oil Gains 1%; Walgreens Posts Upbeat Earnings - Bluejay Diagnostics ( NASDAQ:BJDX ) , CVRx ( NASDAQ:CVRX )

https://www.benzinga.com/25/04/44696357/nasdaq-surges-over-4-walgreens-posts-upbeat-earnings
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 2% on Tuesday. The Dow traded up 2.48% to 38,907.32 while the NASDAQ climbed 2.43% to 15,982.51. The S&P 500 also rose, gaining, 2.38% to 5,182.79. Information technology shares surged by 3.7% on Tuesday.

Dow Jumps Over 1,100 Points; US Small Business Sentiment Falls In March - Bluejay Diagnostics ( NASDAQ:BJDX ) , CVRx ( NASDAQ:CVRX )

https://www.benzinga.com/25/04/44685640/dow-jumps-over-1100-points-us-small-business-sentiment-falls-in-march
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 3% on Tuesday. Following the market opening Tuesday, the Dow traded up 3.03% to 39,114.16 while the NASDAQ climbed 3.31% to 16,120.36. The S&P 500 also rose, gaining, 2.99% to 5,213.75.

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Collective Mining ( AMEX:CNL ) , Celcuity ( NASDAQ:CELC )

https://www.benzinga.com/trading-ideas/movers/25/04/44683326/greenbrier-rpm-international-cvrx-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-s
U.S. stock futures were higher this morning, with the Dow futures gaining more than 900 points on Tuesday. Shares of The Greenbrier Companies, Inc. GBX fell sharply in today's pre-market trading as the company posted downbeat results for its second quarter.
Advertisement

Why Levi Strauss Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - American Rebel Holdings ( NASDAQ:AREB ) , Bluejay Diagnostics ( NASDAQ:BJDX )

https://www.benzinga.com/25/04/44679632/why-levi-strauss-shares-are-trading-higher-by-over-10-here-are-20-stocks-moving-premarket
Shares of Levi Strauss & Co. LEVI rose sharply in today's pre-market trading after reported better-than-expected earnings for its first quarter on Monday. Levi Strauss & Co. reported quarterly adjusted earnings of 38 cents per share, which beat the 28 cent analyst consensus estimate.

CVRx Reports Preliminary First Quarter 2025 Financial Results

https://www.globenewswire.com/news-release/2025/04/07/3057203/0/en/CVRx-Reports-Preliminary-First-Quarter-2025-Financial-Results.html
First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter ...

CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

https://www.globenewswire.com/news-release/2025/02/12/3025369/0/en/CVRx-announces-new-real-world-evidence-demonstrating-significant-reductions-in-healthcare-utilization-with-Barostim.html
New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure ( JCF ) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction New real-world ...

CVRx ( CVRX ) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

https://www.zacks.com/stock/news/2413710/cvrx-cvrx-forms-hammer-chart-pattern-time-for-bottom-fishing
CVRx (CVRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Wall Street Analysts Predict a 25.76% Upside in CVRx ( CVRX ) : Here's What You Should Know

https://www.zacks.com/stock/news/2412067/wall-street-analysts-predict-a-2576-upside-in-cvrx-cvrx-heres-what-you-should-know
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in CVRx (CVRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Advertisement

Skechers Posts Downbeat Results, Joins e.l.f. Beauty, LiveRamp And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Concentra Group Holdings ( NYSE:CON ) , BILL Holdings ( NYSE:BILL )

https://www.benzinga.com/trading-ideas/movers/25/02/43559062/skechers-posts-downbeat-results-joins-e-l-f-beauty-liveramp-and-other-big-stocks-moving-lowe
U.S. stock futures were mixed this morning, with the Dow Jones futures gaining around 0.1% on Friday. Shares of Skechers U.S.A., Inc. SKX fell sharply in today's pre-market trading after the company reported worse-than-expected fourth-quarter financial results and issued first-quarter guidance ...

CVRx ( CVRX ) Reports Q4 Loss, Tops Revenue Estimates

https://www.zacks.com/stock/news/2409580/cvrx-cvrx-reports-q4-loss-tops-revenue-estimates
CVRx (CVRX) delivered earnings and revenue surprises of -16.22% and 0.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Hologic ( HOLX ) Reports Next Week: Wall Street Expects Earnings Growth

https://www.zacks.com/stock/news/2405719/hologic-holx-reports-next-week-wall-street-expects-earnings-growth
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025

https://www.globenewswire.com/news-release/2025/01/21/3013080/0/en/CVRx-to-Report-Fourth-Quarter-2024-Financial-and-Operating-Results-and-Host-Conference-Call-on-February-4-2025.html
MINNEAPOLIS, Jan. 21, 2025 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( "CVRx" ) , a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular ...

CVRx ( CVRX ) Expected to Beat Earnings Estimates: Should You Buy?

https://www.zacks.com/stock/news/2398314/cvrx-cvrx-expected-to-beat-earnings-estimates-should-you-buy
CVRx (CVRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Advertisement

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

https://www.globenewswire.com/news-release/2024/12/23/3001501/0/en/CVRx-to-Present-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference.html
MINNEAPOLIS, Dec. 23, 2024 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( "CVRx" ) , a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025.

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference - CVRx ( NASDAQ:CVRX )

https://www.benzinga.com/pressreleases/24/12/g42661668/cvrx-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference
MINNEAPOLIS, Dec. 23, 2024 ( GLOBE NEWSWIRE ) -- CVRx, Inc. CVRX ( "CVRx" ) , a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025.

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

https://www.globenewswire.com/news-release/2024/11/20/2984785/0/en/CVRx-to-Present-at-the-Piper-Sandler-36th-Annual-Healthcare-Conference.html
MINNEAPOLIS, Nov. 20, 2024 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( "CVRx" ) , a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024.

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference - CVRx ( NASDAQ:CVRX )

https://www.benzinga.com/pressreleases/24/11/g42099634/cvrx-to-present-at-the-piper-sandler-36th-annual-healthcare-conference
MINNEAPOLIS, Nov. 20, 2024 ( GLOBE NEWSWIRE ) -- CVRx, Inc. CVRX ( "CVRx" ) , a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024.

Broadcom To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday - Broadcom ( NASDAQ:AVGO )

https://www.benzinga.com/analyst-ratings/price-target/24/11/41723519/broadcom-to-rally-around-18-here-are-10-top-analyst-forecasts-for-monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B. Riley Securities slashed The Estée Lauder Companies Inc EL price target from $95 to $70. B.
Advertisement

CVRx ( CVRX ) Reports Q3 Loss, Tops Revenue Estimates

https://www.zacks.com/stock/news/2360056/cvrx-cvrx-reports-q3-loss-tops-revenue-estimates
CVRx (CVRX) delivered earnings and revenue surprises of -26.67% and 0.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

CVRx ( CVRX ) Soars 17.2%: Is Further Upside Left in the Stock?

https://www.zacks.com/stock/news/2353976/cvrx-cvrx-soars-172-is-further-upside-left-in-the-stock
CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CVRx announces new CPT® Category I codes for Barostim - CVRx ( NASDAQ:CVRX )

https://www.benzinga.com/pressreleases/24/10/g41408618/cvrx-announces-new-cpt-category-i-codes-for-barostim
MINNEAPOLIS, Oct. 18, 2024 ( GLOBE NEWSWIRE ) -- CVRx, Inc. CVRX ( "CVRx" ) , a commercial-stage medical device company, announced today that the American Medical Association ( AMA ) CPT® Editorial Panel has accepted new Current Procedural Terminology ( CPT ) Category I codes for baroreflex ...

CVRx announces new CPT® Category I codes for Barostim

https://www.globenewswire.com/news-release/2024/10/18/2965705/0/en/CVRx-announces-new-CPT-Category-I-codes-for-Barostim.html
MINNEAPOLIS, Oct. 18, 2024 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( "CVRx" ) , a commercial-stage medical device company, announced today that the American Medical Association ( AMA ) CPT® Editorial Panel has accepted new Current Procedural Terminology ( CPT ) Category I codes for ...

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024

https://www.globenewswire.com/news-release/2024/10/15/2963658/0/en/CVRx-to-Report-Third-Quarter-2024-Financial-and-Operating-Results-and-Host-Conference-Call-on-October-29-2024.html
MINNEAPOLIS, Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( "CVRx" ) , a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular ...
Advertisement

Masimo Surges 8.7%: Is This an Indication of Further Gains? - CVRx ( NASDAQ:CVRX ) , Masimo ( NASDAQ:MASI )

https://www.benzinga.com/news/earnings/24/09/40980131/masimo-surges-8-7-is-this-an-indication-of-further-gains
Masimo MASI shares soared 8.7% in the last trading session to close at $121.42. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8.5% loss over the past four weeks.

Masimo ( MASI ) Surges 8.7%: Is This an Indication of Further Gains?

https://www.zacks.com/stock/news/2339653/masimo-masi-surges-87-is-this-an-indication-of-further-gains
Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CVRX Stock Gains on Unveiling of Barostim's Positive Study Data

https://www.zacks.com/stock/news/2336589/cvrx-stock-gains-on-unveiling-of-barostims-positive-study-data
CVRx announces the publication of positive study data for its Barostim therapy.

CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim - CVRx ( NASDAQ:CVRX )

https://www.benzinga.com/pressreleases/24/09/g40830418/cvrx-announces-new-publication-reinforcing-the-long-term-quality-of-life-benefits-of-barostim
New data published in JACC: Heart Failure demonstrate durable benefits in MLWHF and EQ-5D quality of life measures in heart failure patients with reduced ejection fraction MINNEAPOLIS, Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- CVRx, Inc.

CVRx Announces Appointment of Two New Board Members

https://www.globenewswire.com/news-release/2024/09/03/2939682/0/en/CVRx-Announces-Appointment-of-Two-New-Board-Members.html
Kevin Ballinger and Mitch Hill appointed as new independent Board members Kevin Ballinger and Mitch Hill appointed as new independent Board members ...
Advertisement

Bragar Eagel & Squire, P.C. Is Investigating Arhaus, Cardlytics, and CVRx and Encourages Investors to Contact the Firm - Arhaus ( NASDAQ:ARHS ) , Cardlytics ( NASDAQ:CDLX )

https://www.benzinga.com/pressreleases/24/08/g40566846/bragar-eagel-squire-p-c-is-investigating-arhaus-cardlytics-and-cvrx-and-encourages-investors-to-co
NEW YORK, Aug. 26, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Arhaus, Inc ARHS, Cardlytics, Inc. CDLX, and CVRx, Inc.

CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx, Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the Firm

https://www.benzinga.com/pressreleases/24/08/g40273740/cvrx-alert-bragar-eagel-squire-p-c-is-investigating-cvrx-inc-on-behalf-of-cvrx-stockholders-and-en
NEW YORK, Aug. 08, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CVRx, Inc. ( "CVRx" or the "Company" ) CVRX on behalf of CVRx stockholders.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX - CVRx ( NASDAQ:CVRX )

https://www.benzinga.com/pressreleases/24/08/g40147570/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cvrx-inc-cvrx
NEW YORK, Aug. 03, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ( "CVRx" or the "Company" ) CVRX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

CVRx Announces Increased Inpatient Payment for Barostim Procedure - CVRx ( NASDAQ:CVRX )

https://www.benzinga.com/pressreleases/24/08/g40128426/cvrx-announces-increased-inpatient-payment-for-barostim-procedure
MINNEAPOLIS, Aug. 02, 2024 ( GLOBE NEWSWIRE ) -- CVRx, Inc. CVRX ( "CVRx" ) , a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services ( CMS ) has reassigned the Barostim implant procedure for the inpatient setting as part of the Fiscal Year ( FY ...

CVRx Announces Increased Inpatient Payment for Barostim Procedure

https://www.globenewswire.com/news-release/2024/08/02/2923579/0/en/CVRx-Announces-Increased-Inpatient-Payment-for-Barostim-Procedure.html
MINNEAPOLIS, Aug. 02, 2024 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( "CVRx" ) , a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services ( CMS ) has reassigned the Barostim implant procedure for the inpatient setting as part of the ...
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion